APGE Company Profile and Key Details

APGE has shown sold momentum, gaining 5.65% over the past week and 48.76% over the past quarter, though year-to-date performance is up 8.69%. Short-term trend indicators are mixed aligned (SMA20 2.49%, SMA50 -5.69%, SMA200 30.48%). The stock’s 14-day RSI is 48.05 (neutral), while the ATR of 3.67 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -18.29% below its high and over 163.7% above its low. Average 10-day trading volume of 2.44 million shares is below the 3-month average of 2.83 million, indicating normal recent market interest.

Apogee Therapeutics, Inc. has 62.20 million shares outstanding. The public float is 58.44 million shares, elevated short interest at 7.28% of float. This equals 4.27 million shares. The short ratio is 3.63 days. Institutional investors hold 111.86% of the float. Insiders own 2.33%. HENDERSON MICHAEL THOMAS holds 995.99 thousand shares, Shah Nimish P has 365.85 thousand shares and Fairmount Funds Management LLC has 298.65 thousand shares. Over the past six months, insider transactions show net selling. They sold 153.60 thousand shares across 14 transactions.

Apogee Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.02. This means the shares are trading above this model’s fair value.

Wall Street analysts project EPS growth of -21.06% annually over the next five years. Analyst sentiment is neutral. Analyst rating data shows there are 7 Strong Buy ratings, 12 Buy ratings, 13 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $160.00 to $60.00. The high target offers 18.46% upside. The low target suggests -55.58% downside. The mean target is $116.73. This offers -13.58% upside. Apogee Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended August 10, 2026, missed forecasts by 6.54%. The prior quarter beat by -5.36%. Over the last six quarters, Apple has recorded several small beats. These include -20.17% in May 12, 2025.

The stock is currently trading near its 52-week high $35.39 and $135.09. With a market capitalization of about $8.36 billion, Apogee Therapeutics, Inc. is classified as a mid-cap and shows lower-than-market volatility (beta ~0.34). Key stats such as the average daily volume over the past year has been around 2.82 million shares, volume is running light vs its 52-week average. Headquartered in Waltham, MA, Apogee Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Michael Thomas Henderson, the company employs approximately 261 people and listed since July 14, 2023. Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders.

Apogee Therapeutics, Inc. trades at a P/E ratio of -31.12, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 8.53 trading at moderately above to book value. The P/FCF stands at -34.26, also below market averages.

Our AI price prediction model suggests that Apogee Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.42%, with price expected at $135.64 by September 16, 2026, within a range of $131.11 to $140.68 3-Month Outlook: Projected rise of 116.43%, reaching $292.33 by December 01, 2026, with a range of $290.44 to $294.60. 1-Year Outlook: Projected gain of 15.58%, with price at $156.11 by September 02, 2027, within a range of $148.57 to $162.58.

Apogee Therapeutics, Inc. (NASDAQ:APGE) shares are flat 8.69% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Apogee Therapeutics, Inc. trading at a premium to the broader market with a P/E of -31.12. Analyst sentiment is mixed, with the majority of ratings in Hold territory and a mean price target of $109.15, suggesting -19.19% downside. Our AI forecast model points to short-term strength (0.42% over two weeks), a medium-term rise (116.43% over three months), and a longer-term gain (15.58% over one year), with expected trading ranges indicating moderate volatility.